Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events

Biotech Investing

Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that its REDUCE-IT cardiovascular outcomes study of Vascepa (icosapent ethyl) is estimated to have reached the onset of the targeted 1,612 primary major adverse cardiovascular events (MACE) specified in the study design. As quoted in …

Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that its REDUCE-IT cardiovascular outcomes study of Vascepa (icosapent ethyl) is estimated to have reached the onset of the targeted 1,612 primary major adverse cardiovascular events (MACE) specified in the study design.

As quoted in the press release:

Amarin maintains its guidance to report top-line results from the study before the end of Q3 2018.

“We are excited to be nearing conclusion of this potentially landmark cardiovascular outcomes study,” commented Dr. Steven Ketchum, president of R&D and chief scientific officer of Amarin. “We appreciate the continued dedication of patients participating in this important study and the continued commitment and hard work at the clinical sites and by the many professionals involved in study conduct and completion. We will work diligently to rapidly roll-up and report the results of the study in the hope that such results can lead to better informed preventative care of patients at high cardiovascular risk.”

Click here to read the full press release.

The Conversation (0)
×